nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—Retinoids—Alitretinoin—hematologic cancer	0.556	1	CiPCiCtD
Bexarotene—RXRG—Alitretinoin—hematologic cancer	0.0771	0.272	CbGbCtD
Bexarotene—RXRB—Alitretinoin—hematologic cancer	0.0681	0.241	CbGbCtD
Bexarotene—RXRA—Alitretinoin—hematologic cancer	0.0681	0.241	CbGbCtD
Bexarotene—CYP2C9—Idarubicin—hematologic cancer	0.00542	0.0191	CbGbCtD
Bexarotene—CYP2C9—Bortezomib—hematologic cancer	0.00401	0.0142	CbGbCtD
Bexarotene—CYP3A4—Busulfan—hematologic cancer	0.00354	0.0125	CbGbCtD
Bexarotene—CYP3A4—Lomustine—hematologic cancer	0.00354	0.0125	CbGbCtD
Bexarotene—CYP2C9—Thalidomide—hematologic cancer	0.00349	0.0123	CbGbCtD
Bexarotene—CYP2C9—Teniposide—hematologic cancer	0.00333	0.0118	CbGbCtD
Bexarotene—CYP3A4—Thiotepa—hematologic cancer	0.00315	0.0111	CbGbCtD
Bexarotene—CYP2C9—Ifosfamide—hematologic cancer	0.00307	0.0109	CbGbCtD
Bexarotene—CYP2C9—Imatinib—hematologic cancer	0.00294	0.0104	CbGbCtD
Bexarotene—CYP2C9—Nilotinib—hematologic cancer	0.00267	0.00943	CbGbCtD
Bexarotene—Tamibarotene—RARA—hematologic cancer	0.00262	1	CrCbGaD
Bexarotene—CYP3A4—Methoxsalen—hematologic cancer	0.00245	0.00866	CbGbCtD
Bexarotene—CYP3A4—Bortezomib—hematologic cancer	0.00233	0.00824	CbGbCtD
Bexarotene—CYP3A4—Daunorubicin—hematologic cancer	0.00223	0.00788	CbGbCtD
Bexarotene—CYP3A4—Cytarabine—hematologic cancer	0.00197	0.00695	CbGbCtD
Bexarotene—CYP3A4—Teniposide—hematologic cancer	0.00194	0.00684	CbGbCtD
Bexarotene—CYP3A4—Ifosfamide—hematologic cancer	0.00179	0.00632	CbGbCtD
Bexarotene—CYP3A4—Imatinib—hematologic cancer	0.00171	0.00603	CbGbCtD
Bexarotene—CYP3A4—Ruxolitinib—hematologic cancer	0.00161	0.00568	CbGbCtD
Bexarotene—CYP3A4—Nilotinib—hematologic cancer	0.00155	0.00548	CbGbCtD
Bexarotene—CYP3A4—Vinorelbine—hematologic cancer	0.00154	0.00544	CbGbCtD
Bexarotene—CYP2C9—Cisplatin—hematologic cancer	0.0015	0.00528	CbGbCtD
Bexarotene—CYP3A4—Triamcinolone—hematologic cancer	0.00141	0.00497	CbGbCtD
Bexarotene—CYP3A4—Dasatinib—hematologic cancer	0.00137	0.00485	CbGbCtD
Bexarotene—CYP3A4—Mitoxantrone—hematologic cancer	0.00136	0.00479	CbGbCtD
Bexarotene—CYP2C9—Dexamethasone—hematologic cancer	0.00121	0.00427	CbGbCtD
Bexarotene—CYP3A4—Betamethasone—hematologic cancer	0.00121	0.00427	CbGbCtD
Bexarotene—CYP3A4—Prednisolone—hematologic cancer	0.00119	0.00421	CbGbCtD
Bexarotene—CYP3A4—Prednisone—hematologic cancer	0.00113	0.00398	CbGbCtD
Bexarotene—CYP3A4—Irinotecan—hematologic cancer	0.00107	0.00377	CbGbCtD
Bexarotene—CYP3A4—Vinblastine—hematologic cancer	0.000948	0.00335	CbGbCtD
Bexarotene—CYP3A4—Vincristine—hematologic cancer	0.000932	0.00329	CbGbCtD
Bexarotene—CYP3A4—Etoposide—hematologic cancer	0.000854	0.00302	CbGbCtD
Bexarotene—CYP3A4—Dexamethasone—hematologic cancer	0.000703	0.00248	CbGbCtD
Bexarotene—CYP3A4—Doxorubicin—hematologic cancer	0.000583	0.00206	CbGbCtD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—hematologic cancer	8.52e-06	0.000185	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—ESR1—hematologic cancer	8.39e-06	0.000183	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—IDH1—hematologic cancer	8.33e-06	0.000181	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	8.33e-06	0.000181	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	8.26e-06	0.00018	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH1—hematologic cancer	8.25e-06	0.00018	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ABCC3—hematologic cancer	8.24e-06	0.000179	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TXN—hematologic cancer	8.24e-06	0.000179	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTO1—hematologic cancer	8.24e-06	0.000179	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAPK14—hematologic cancer	8.19e-06	0.000178	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—EIF4EBP1—hematologic cancer	8.12e-06	0.000177	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—HSPB1—hematologic cancer	8.12e-06	0.000177	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH1—hematologic cancer	8.11e-06	0.000176	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CDK4—hematologic cancer	8.07e-06	0.000176	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MET—hematologic cancer	8.07e-06	0.000176	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SPHK1—hematologic cancer	8.06e-06	0.000175	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MAPK14—hematologic cancer	8.04e-06	0.000175	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—ESR1—hematologic cancer	7.89e-06	0.000172	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SMC1A—hematologic cancer	7.78e-06	0.000169	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NOTCH1—hematologic cancer	7.77e-06	0.000169	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—UGT1A1—hematologic cancer	7.75e-06	0.000169	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	7.64e-06	0.000166	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH1—hematologic cancer	7.63e-06	0.000166	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—H3F3A—hematologic cancer	7.62e-06	0.000166	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	7.59e-06	0.000165	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CRABP1—hematologic cancer	7.54e-06	0.000164	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SLC22A1—hematologic cancer	7.54e-06	0.000164	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—CREBBP—hematologic cancer	7.48e-06	0.000163	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PTPN11—hematologic cancer	7.46e-06	0.000162	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—FTCD—hematologic cancer	7.41e-06	0.000161	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PHYH—hematologic cancer	7.41e-06	0.000161	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GMPS—hematologic cancer	7.41e-06	0.000161	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—CREBBP—hematologic cancer	7.35e-06	0.00016	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALOX5—hematologic cancer	7.34e-06	0.00016	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	7.34e-06	0.00016	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	7.33e-06	0.00016	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—EZH2—hematologic cancer	7.31e-06	0.000159	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CREB1—hematologic cancer	7.23e-06	0.000157	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PARP1—hematologic cancer	7.16e-06	0.000156	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NUP98—hematologic cancer	7.11e-06	0.000155	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6R—hematologic cancer	7.05e-06	0.000154	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CREBBP—hematologic cancer	7.04e-06	0.000153	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	6.99e-06	0.000152	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—CREBBP—hematologic cancer	6.91e-06	0.00015	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	6.91e-06	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—HDAC2—hematologic cancer	6.91e-06	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NCOA3—hematologic cancer	6.9e-06	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ADCY7—hematologic cancer	6.9e-06	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NUP214—hematologic cancer	6.86e-06	0.000149	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.79e-06	0.000148	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SMPD3—hematologic cancer	6.78e-06	0.000147	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	6.76e-06	0.000147	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAP2K1—hematologic cancer	6.72e-06	0.000146	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—MTR—hematologic cancer	6.72e-06	0.000146	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ABCG2—hematologic cancer	6.72e-06	0.000146	CbGpPWpGaD
Bexarotene—Nervous system disorder—Prednisone—hematologic cancer	6.62e-06	5.92e-05	CcSEcCtD
Bexarotene—Tachycardia—Prednisone—hematologic cancer	6.59e-06	5.89e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—ENO2—hematologic cancer	6.59e-06	0.000143	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—hematologic cancer	6.57e-06	5.87e-05	CcSEcCtD
Bexarotene—Skin disorder—Prednisone—hematologic cancer	6.56e-06	5.86e-05	CcSEcCtD
Bexarotene—Nausea—Gemcitabine—hematologic cancer	6.56e-06	5.86e-05	CcSEcCtD
Bexarotene—Vomiting—Cisplatin—hematologic cancer	6.54e-06	5.85e-05	CcSEcCtD
Bexarotene—Hyperhidrosis—Prednisone—hematologic cancer	6.53e-06	5.84e-05	CcSEcCtD
Bexarotene—Rash—Cisplatin—hematologic cancer	6.49e-06	5.8e-05	CcSEcCtD
Bexarotene—Dermatitis—Cisplatin—hematologic cancer	6.48e-06	5.79e-05	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—hematologic cancer	6.47e-06	5.79e-05	CcSEcCtD
Bexarotene—Erythema—Epirubicin—hematologic cancer	6.47e-06	5.79e-05	CcSEcCtD
Bexarotene—Diarrhoea—Etoposide—hematologic cancer	6.45e-06	5.76e-05	CcSEcCtD
Bexarotene—Anorexia—Prednisone—hematologic cancer	6.44e-06	5.76e-05	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—hematologic cancer	6.43e-06	5.75e-05	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—hematologic cancer	6.42e-06	5.74e-05	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—hematologic cancer	6.41e-06	5.73e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—FGF2—hematologic cancer	6.4e-06	0.000139	CbGpPWpGaD
Bexarotene—Anaemia—Methotrexate—hematologic cancer	6.39e-06	5.71e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Dexamethasone—hematologic cancer	6.39e-06	5.71e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Betamethasone—hematologic cancer	6.39e-06	5.71e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—GSTT1—hematologic cancer	6.39e-06	0.000139	CbGpPWpGaD
Bexarotene—Cardiac disorder—Doxorubicin—hematologic cancer	6.39e-06	5.71e-05	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—hematologic cancer	6.38e-06	5.7e-05	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	6.38e-06	0.000139	CbGpPWpGaD
Bexarotene—Tension—Epirubicin—hematologic cancer	6.35e-06	5.68e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Betamethasone—hematologic cancer	6.34e-06	5.67e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.34e-06	5.67e-05	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—hematologic cancer	6.34e-06	5.67e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	6.32e-06	0.000137	CbGpPWpGaD
Bexarotene—Hypersensitivity—Triamcinolone—hematologic cancer	6.3e-06	5.63e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.29e-06	0.000137	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	6.29e-06	0.000137	CbGpPWpGaD
Bexarotene—Nervousness—Epirubicin—hematologic cancer	6.29e-06	5.62e-05	CcSEcCtD
Bexarotene—Back pain—Epirubicin—hematologic cancer	6.26e-06	5.6e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—SDC1—hematologic cancer	6.24e-06	0.000136	CbGpPWpGaD
Bexarotene—Angiopathy—Doxorubicin—hematologic cancer	6.24e-06	5.58e-05	CcSEcCtD
Bexarotene—Malaise—Methotrexate—hematologic cancer	6.24e-06	5.58e-05	CcSEcCtD
Bexarotene—Dizziness—Etoposide—hematologic cancer	6.23e-06	5.57e-05	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—hematologic cancer	6.22e-06	5.56e-05	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—hematologic cancer	6.21e-06	5.56e-05	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	6.2e-06	0.000135	CbGpPWpGaD
Bexarotene—Leukopenia—Methotrexate—hematologic cancer	6.19e-06	5.53e-05	CcSEcCtD
Bexarotene—Chills—Doxorubicin—hematologic cancer	6.17e-06	5.52e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	6.16e-06	0.000134	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.15e-06	5.5e-05	CcSEcCtD
Bexarotene—Dizziness—Prednisolone—hematologic cancer	6.15e-06	5.49e-05	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—hematologic cancer	6.15e-06	5.49e-05	CcSEcCtD
Bexarotene—Asthenia—Triamcinolone—hematologic cancer	6.13e-06	5.48e-05	CcSEcCtD
Bexarotene—Body temperature increased—Betamethasone—hematologic cancer	6.13e-06	5.48e-05	CcSEcCtD
Bexarotene—Body temperature increased—Dexamethasone—hematologic cancer	6.13e-06	5.48e-05	CcSEcCtD
Bexarotene—Abdominal pain—Betamethasone—hematologic cancer	6.13e-06	5.48e-05	CcSEcCtD
Bexarotene—Abdominal pain—Dexamethasone—hematologic cancer	6.13e-06	5.48e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—JAK2—hematologic cancer	6.13e-06	0.000133	CbGpPWpGaD
Bexarotene—Nausea—Cisplatin—hematologic cancer	6.11e-06	5.46e-05	CcSEcCtD
Bexarotene—Insomnia—Prednisone—hematologic cancer	6.11e-06	5.46e-05	CcSEcCtD
Bexarotene—Alopecia—Doxorubicin—hematologic cancer	6.08e-06	5.43e-05	CcSEcCtD
Bexarotene—Paraesthesia—Prednisone—hematologic cancer	6.07e-06	5.42e-05	CcSEcCtD
Bexarotene—Pruritus—Triamcinolone—hematologic cancer	6.05e-06	5.41e-05	CcSEcCtD
Bexarotene—Cough—Methotrexate—hematologic cancer	6.04e-06	5.4e-05	CcSEcCtD
Bexarotene—Ill-defined disorder—Epirubicin—hematologic cancer	6.01e-06	5.37e-05	CcSEcCtD
Bexarotene—Vomiting—Etoposide—hematologic cancer	5.99e-06	5.36e-05	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—hematologic cancer	5.99e-06	5.35e-05	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—hematologic cancer	5.99e-06	5.35e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—AR—hematologic cancer	5.99e-06	0.00013	CbGpPWpGaD
Bexarotene—Anaemia—Epirubicin—hematologic cancer	5.98e-06	5.35e-05	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.98e-06	0.00013	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.96e-06	0.00013	CbGpPWpGaD
Bexarotene—Agitation—Epirubicin—hematologic cancer	5.95e-06	5.32e-05	CcSEcCtD
Bexarotene—Dyspepsia—Prednisone—hematologic cancer	5.95e-06	5.32e-05	CcSEcCtD
Bexarotene—Rash—Etoposide—hematologic cancer	5.94e-06	5.31e-05	CcSEcCtD
Bexarotene—Dermatitis—Etoposide—hematologic cancer	5.94e-06	5.31e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—B3GAT1—hematologic cancer	5.92e-06	0.000129	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ASNS—hematologic cancer	5.92e-06	0.000129	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—DCK—hematologic cancer	5.92e-06	0.000129	CbGpPWpGaD
Bexarotene—Headache—Etoposide—hematologic cancer	5.9e-06	5.28e-05	CcSEcCtD
Bexarotene—Flatulence—Doxorubicin—hematologic cancer	5.9e-06	5.28e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.89e-06	0.000128	CbGpPWpGaD
Bexarotene—Myalgia—Methotrexate—hematologic cancer	5.89e-06	5.26e-05	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—hematologic cancer	5.89e-06	5.26e-05	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—hematologic cancer	5.89e-06	5.26e-05	CcSEcCtD
Bexarotene—Tension—Doxorubicin—hematologic cancer	5.88e-06	5.25e-05	CcSEcCtD
Bexarotene—Decreased appetite—Prednisone—hematologic cancer	5.87e-06	5.25e-05	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—hematologic cancer	5.86e-06	5.24e-05	CcSEcCtD
Bexarotene—Rash—Prednisolone—hematologic cancer	5.86e-06	5.24e-05	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	5.86e-06	0.000127	CbGpPWpGaD
Bexarotene—Dermatitis—Prednisolone—hematologic cancer	5.86e-06	5.23e-05	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.85e-06	5.23e-05	CcSEcCtD
Bexarotene—Malaise—Epirubicin—hematologic cancer	5.84e-06	5.22e-05	CcSEcCtD
Bexarotene—Fatigue—Prednisone—hematologic cancer	5.82e-06	5.21e-05	CcSEcCtD
Bexarotene—Headache—Prednisolone—hematologic cancer	5.82e-06	5.21e-05	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—hematologic cancer	5.82e-06	5.2e-05	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—hematologic cancer	5.82e-06	5.2e-05	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—hematologic cancer	5.82e-06	5.2e-05	CcSEcCtD
Bexarotene—Syncope—Epirubicin—hematologic cancer	5.8e-06	5.19e-05	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—hematologic cancer	5.79e-06	5.18e-05	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—hematologic cancer	5.79e-06	5.18e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	5.79e-06	0.000126	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	5.78e-06	0.000126	CbGpPWpGaD
Bexarotene—Constipation—Prednisone—hematologic cancer	5.78e-06	5.16e-05	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—hematologic cancer	5.76e-06	5.15e-05	CcSEcCtD
Bexarotene—Palpitations—Epirubicin—hematologic cancer	5.72e-06	5.11e-05	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—hematologic cancer	5.69e-06	5.09e-05	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—hematologic cancer	5.69e-06	5.09e-05	CcSEcCtD
Bexarotene—Dizziness—Triamcinolone—hematologic cancer	5.65e-06	5.05e-05	CcSEcCtD
Bexarotene—Cough—Epirubicin—hematologic cancer	5.65e-06	5.05e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.63e-06	0.000123	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HDC—hematologic cancer	5.61e-06	0.000122	CbGpPWpGaD
Bexarotene—Infection—Methotrexate—hematologic cancer	5.61e-06	5.01e-05	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—ALB—hematologic cancer	5.6e-06	0.000122	CbGpPWpGaD
Bexarotene—Nausea—Etoposide—hematologic cancer	5.6e-06	5e-05	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—hematologic cancer	5.59e-06	5e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Prednisone—hematologic cancer	5.57e-06	4.98e-05	CcSEcCtD
Bexarotene—Asthenia—Betamethasone—hematologic cancer	5.56e-06	4.97e-05	CcSEcCtD
Bexarotene—Asthenia—Dexamethasone—hematologic cancer	5.56e-06	4.97e-05	CcSEcCtD
Bexarotene—Ill-defined disorder—Doxorubicin—hematologic cancer	5.56e-06	4.97e-05	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—hematologic cancer	5.54e-06	4.95e-05	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—hematologic cancer	5.54e-06	4.95e-05	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—hematologic cancer	5.53e-06	4.94e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Prednisone—hematologic cancer	5.52e-06	4.94e-05	CcSEcCtD
Bexarotene—Nausea—Prednisolone—hematologic cancer	5.52e-06	4.94e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—CDKN2B—hematologic cancer	5.52e-06	0.00012	CbGpPWpGaD
Bexarotene—Myalgia—Epirubicin—hematologic cancer	5.51e-06	4.93e-05	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—hematologic cancer	5.51e-06	4.93e-05	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—hematologic cancer	5.51e-06	4.93e-05	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—hematologic cancer	5.5e-06	4.92e-05	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—hematologic cancer	5.49e-06	4.91e-05	CcSEcCtD
Bexarotene—Pruritus—Dexamethasone—hematologic cancer	5.49e-06	4.91e-05	CcSEcCtD
Bexarotene—Pruritus—Betamethasone—hematologic cancer	5.49e-06	4.91e-05	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—hematologic cancer	5.48e-06	4.9e-05	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.47e-06	4.89e-05	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—hematologic cancer	5.46e-06	4.88e-05	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—hematologic cancer	5.44e-06	4.87e-05	CcSEcCtD
Bexarotene—Vomiting—Triamcinolone—hematologic cancer	5.43e-06	4.86e-05	CcSEcCtD
Bexarotene—Malaise—Doxorubicin—hematologic cancer	5.4e-06	4.83e-05	CcSEcCtD
Bexarotene—Rash—Triamcinolone—hematologic cancer	5.39e-06	4.82e-05	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—hematologic cancer	5.39e-06	4.82e-05	CcSEcCtD
Bexarotene—Dermatitis—Triamcinolone—hematologic cancer	5.38e-06	4.81e-05	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—hematologic cancer	5.38e-06	4.81e-05	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—hematologic cancer	5.38e-06	4.81e-05	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—hematologic cancer	5.37e-06	4.8e-05	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—hematologic cancer	5.36e-06	4.79e-05	CcSEcCtD
Bexarotene—Headache—Triamcinolone—hematologic cancer	5.35e-06	4.79e-05	CcSEcCtD
Bexarotene—Abdominal pain—Prednisone—hematologic cancer	5.34e-06	4.77e-05	CcSEcCtD
Bexarotene—Body temperature increased—Prednisone—hematologic cancer	5.34e-06	4.77e-05	CcSEcCtD
Bexarotene—Confusional state—Epirubicin—hematologic cancer	5.33e-06	4.76e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—CD44—hematologic cancer	5.31e-06	0.000116	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NQO1—hematologic cancer	5.31e-06	0.000116	CbGpPWpGaD
Bexarotene—Diarrhoea—Dexamethasone—hematologic cancer	5.31e-06	4.74e-05	CcSEcCtD
Bexarotene—Diarrhoea—Betamethasone—hematologic cancer	5.31e-06	4.74e-05	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—hematologic cancer	5.29e-06	4.73e-05	CcSEcCtD
Bexarotene—Oedema—Epirubicin—hematologic cancer	5.28e-06	4.72e-05	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—hematologic cancer	5.26e-06	4.71e-05	CcSEcCtD
Bexarotene—Infection—Epirubicin—hematologic cancer	5.25e-06	4.69e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	5.23e-06	0.000114	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NCOR1—hematologic cancer	5.23e-06	0.000114	CbGpPWpGaD
Bexarotene—Cough—Doxorubicin—hematologic cancer	5.23e-06	4.67e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.2e-06	0.000113	CbGpPWpGaD
Bexarotene—Shock—Epirubicin—hematologic cancer	5.2e-06	4.65e-05	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—hematologic cancer	5.18e-06	4.63e-05	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—hematologic cancer	5.17e-06	4.62e-05	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—hematologic cancer	5.17e-06	4.62e-05	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—hematologic cancer	5.16e-06	4.61e-05	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.14e-06	4.6e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—CDA—hematologic cancer	5.13e-06	0.000112	CbGpPWpGaD
Bexarotene—Skin disorder—Epirubicin—hematologic cancer	5.13e-06	4.59e-05	CcSEcCtD
Bexarotene—Dizziness—Betamethasone—hematologic cancer	5.13e-06	4.58e-05	CcSEcCtD
Bexarotene—Dizziness—Dexamethasone—hematologic cancer	5.13e-06	4.58e-05	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—hematologic cancer	5.11e-06	4.57e-05	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—hematologic cancer	5.11e-06	4.56e-05	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—hematologic cancer	5.1e-06	4.56e-05	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—hematologic cancer	5.1e-06	4.56e-05	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—hematologic cancer	5.1e-06	4.56e-05	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—hematologic cancer	5.08e-06	4.54e-05	CcSEcCtD
Bexarotene—Nausea—Triamcinolone—hematologic cancer	5.08e-06	4.54e-05	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—hematologic cancer	5.07e-06	4.53e-05	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.06e-06	4.53e-05	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—hematologic cancer	5.04e-06	4.5e-05	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—hematologic cancer	5.04e-06	4.5e-05	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—hematologic cancer	5.03e-06	4.5e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—CYCS—hematologic cancer	5.02e-06	0.000109	CbGpPWpGaD
Bexarotene—Somnolence—Methotrexate—hematologic cancer	5.02e-06	4.49e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—HSP90AA1—hematologic cancer	4.99e-06	0.000109	CbGpPWpGaD
Bexarotene—Dry mouth—Doxorubicin—hematologic cancer	4.99e-06	4.46e-05	CcSEcCtD
Bexarotene—Hypersensitivity—Prednisone—hematologic cancer	4.98e-06	4.45e-05	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—hematologic cancer	4.97e-06	4.44e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—PC—hematologic cancer	4.94e-06	0.000108	CbGpPWpGaD
Bexarotene—Vomiting—Dexamethasone—hematologic cancer	4.93e-06	4.41e-05	CcSEcCtD
Bexarotene—Vomiting—Betamethasone—hematologic cancer	4.93e-06	4.41e-05	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—hematologic cancer	4.93e-06	4.41e-05	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—hematologic cancer	4.91e-06	4.39e-05	CcSEcCtD
Bexarotene—Rash—Betamethasone—hematologic cancer	4.89e-06	4.37e-05	CcSEcCtD
Bexarotene—Rash—Dexamethasone—hematologic cancer	4.89e-06	4.37e-05	CcSEcCtD
Bexarotene—Oedema—Doxorubicin—hematologic cancer	4.89e-06	4.37e-05	CcSEcCtD
Bexarotene—CYP3A4—Metabolism—GMPS—hematologic cancer	4.89e-06	0.000106	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—FTCD—hematologic cancer	4.89e-06	0.000106	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PHYH—hematologic cancer	4.89e-06	0.000106	CbGpPWpGaD
Bexarotene—Dermatitis—Dexamethasone—hematologic cancer	4.89e-06	4.37e-05	CcSEcCtD
Bexarotene—Dermatitis—Betamethasone—hematologic cancer	4.89e-06	4.37e-05	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.87e-06	4.36e-05	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—hematologic cancer	4.87e-06	4.35e-05	CcSEcCtD
Bexarotene—Headache—Dexamethasone—hematologic cancer	4.86e-06	4.34e-05	CcSEcCtD
Bexarotene—Headache—Betamethasone—hematologic cancer	4.86e-06	4.34e-05	CcSEcCtD
Bexarotene—Infection—Doxorubicin—hematologic cancer	4.86e-06	4.34e-05	CcSEcCtD
Bexarotene—Asthenia—Prednisone—hematologic cancer	4.85e-06	4.33e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—NR3C1—hematologic cancer	4.84e-06	0.000105	CbGpPWpGaD
Bexarotene—Pain—Methotrexate—hematologic cancer	4.83e-06	4.32e-05	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.81e-06	4.3e-05	CcSEcCtD
Bexarotene—Shock—Doxorubicin—hematologic cancer	4.81e-06	4.3e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—EP300—hematologic cancer	4.8e-06	0.000104	CbGpPWpGaD
Bexarotene—Nervous system disorder—Doxorubicin—hematologic cancer	4.79e-06	4.29e-05	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—hematologic cancer	4.79e-06	4.28e-05	CcSEcCtD
Bexarotene—Pruritus—Prednisone—hematologic cancer	4.78e-06	4.27e-05	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—hematologic cancer	4.78e-06	4.27e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—GBA—hematologic cancer	4.77e-06	0.000104	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC35B2—hematologic cancer	4.77e-06	0.000104	CbGpPWpGaD
Bexarotene—Tachycardia—Doxorubicin—hematologic cancer	4.77e-06	4.26e-05	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—hematologic cancer	4.75e-06	4.24e-05	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—hematologic cancer	4.74e-06	4.24e-05	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—hematologic cancer	4.73e-06	4.22e-05	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—hematologic cancer	4.71e-06	4.21e-05	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—hematologic cancer	4.7e-06	4.2e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—SRC—hematologic cancer	4.67e-06	0.000102	CbGpPWpGaD
Bexarotene—Anorexia—Doxorubicin—hematologic cancer	4.66e-06	4.17e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Methotrexate—hematologic cancer	4.65e-06	4.16e-05	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—hematologic cancer	4.65e-06	4.16e-05	CcSEcCtD
Bexarotene—Diarrhoea—Prednisone—hematologic cancer	4.62e-06	4.13e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—hematologic cancer	4.62e-06	4.13e-05	CcSEcCtD
Bexarotene—Nausea—Dexamethasone—hematologic cancer	4.61e-06	4.12e-05	CcSEcCtD
Bexarotene—Nausea—Betamethasone—hematologic cancer	4.61e-06	4.12e-05	CcSEcCtD
Bexarotene—Decreased appetite—Epirubicin—hematologic cancer	4.59e-06	4.11e-05	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.56e-06	4.08e-05	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—hematologic cancer	4.55e-06	4.07e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—VEGFA—hematologic cancer	4.54e-06	9.89e-05	CbGpPWpGaD
Bexarotene—Pain—Epirubicin—hematologic cancer	4.52e-06	4.04e-05	CcSEcCtD
Bexarotene—Constipation—Epirubicin—hematologic cancer	4.52e-06	4.04e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—STAT3—hematologic cancer	4.5e-06	9.79e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.49e-06	9.78e-05	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NRAS—hematologic cancer	4.49e-06	9.77e-05	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MAPK3—hematologic cancer	4.49e-06	9.76e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SMPD3—hematologic cancer	4.47e-06	9.72e-05	CbGpPWpGaD
Bexarotene—Dizziness—Prednisone—hematologic cancer	4.47e-06	3.99e-05	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—hematologic cancer	4.46e-06	3.99e-05	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—hematologic cancer	4.46e-06	3.99e-05	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.45e-06	3.98e-05	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—hematologic cancer	4.44e-06	9.66e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTP1—hematologic cancer	4.43e-06	9.64e-05	CbGpPWpGaD
Bexarotene—Insomnia—Doxorubicin—hematologic cancer	4.42e-06	3.95e-05	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—hematologic cancer	4.39e-06	3.92e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—MTAP—hematologic cancer	4.37e-06	9.5e-05	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—hematologic cancer	4.36e-06	9.5e-05	CbGpPWpGaD
Bexarotene—Dyspnoea—Doxorubicin—hematologic cancer	4.36e-06	3.9e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—hematologic cancer	4.35e-06	3.89e-05	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—hematologic cancer	4.35e-06	3.88e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—hematologic cancer	4.32e-06	3.86e-05	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—hematologic cancer	4.3e-06	3.85e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—MAPK3—hematologic cancer	4.3e-06	9.35e-05	CbGpPWpGaD
Bexarotene—Vomiting—Prednisone—hematologic cancer	4.29e-06	3.84e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.28e-06	9.32e-05	CbGpPWpGaD
Bexarotene—Rash—Prednisone—hematologic cancer	4.26e-06	3.81e-05	CcSEcCtD
Bexarotene—Dermatitis—Prednisone—hematologic cancer	4.25e-06	3.8e-05	CcSEcCtD
Bexarotene—Decreased appetite—Doxorubicin—hematologic cancer	4.25e-06	3.8e-05	CcSEcCtD
Bexarotene—Headache—Prednisone—hematologic cancer	4.23e-06	3.78e-05	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.22e-06	3.77e-05	CcSEcCtD
Bexarotene—RXRB—Gene Expression—MAPK3—hematologic cancer	4.22e-06	9.18e-05	CbGpPWpGaD
Bexarotene—Fatigue—Doxorubicin—hematologic cancer	4.21e-06	3.77e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—ABCB1—hematologic cancer	4.19e-06	9.12e-05	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MAPK14—hematologic cancer	4.19e-06	9.12e-05	CbGpPWpGaD
Bexarotene—Constipation—Doxorubicin—hematologic cancer	4.18e-06	3.74e-05	CcSEcCtD
Bexarotene—Pain—Doxorubicin—hematologic cancer	4.18e-06	3.74e-05	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—hematologic cancer	4.18e-06	3.73e-05	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—hematologic cancer	4.18e-06	3.73e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—TGFB1—hematologic cancer	4.17e-06	9.07e-05	CbGpPWpGaD
Bexarotene—Hypersensitivity—Methotrexate—hematologic cancer	4.16e-06	3.72e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—ESR1—hematologic cancer	4.11e-06	8.95e-05	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—hematologic cancer	4.1e-06	8.93e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NCOR1—hematologic cancer	4.07e-06	8.86e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTM1—hematologic cancer	4.07e-06	8.86e-05	CbGpPWpGaD
Bexarotene—Asthenia—Methotrexate—hematologic cancer	4.05e-06	3.62e-05	CcSEcCtD
Bexarotene—Feeling abnormal—Doxorubicin—hematologic cancer	4.03e-06	3.6e-05	CcSEcCtD
Bexarotene—Nausea—Prednisone—hematologic cancer	4.01e-06	3.59e-05	CcSEcCtD
Bexarotene—Gastrointestinal pain—Doxorubicin—hematologic cancer	4e-06	3.57e-05	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—hematologic cancer	3.99e-06	3.57e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—NOTCH1—hematologic cancer	3.97e-06	8.65e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—DCK—hematologic cancer	3.91e-06	8.5e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ASNS—hematologic cancer	3.91e-06	8.5e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—B3GAT1—hematologic cancer	3.91e-06	8.5e-05	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—hematologic cancer	3.89e-06	8.47e-05	CbGpPWpGaD
Bexarotene—Hypersensitivity—Epirubicin—hematologic cancer	3.89e-06	3.48e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—FHL2—hematologic cancer	3.89e-06	8.47e-05	CbGpPWpGaD
Bexarotene—Body temperature increased—Doxorubicin—hematologic cancer	3.86e-06	3.45e-05	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—hematologic cancer	3.86e-06	3.45e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—KRAS—hematologic cancer	3.86e-06	8.41e-05	CbGpPWpGaD
Bexarotene—Diarrhoea—Methotrexate—hematologic cancer	3.86e-06	3.45e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—AGRN—hematologic cancer	3.82e-06	8.3e-05	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—hematologic cancer	3.79e-06	3.39e-05	CcSEcCtD
Bexarotene—Pruritus—Epirubicin—hematologic cancer	3.74e-06	3.34e-05	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—hematologic cancer	3.73e-06	3.34e-05	CcSEcCtD
Bexarotene—CYP3A4—Metabolism—HDC—hematologic cancer	3.7e-06	8.06e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—IDH2—hematologic cancer	3.62e-06	7.87e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HMMR—hematologic cancer	3.62e-06	7.87e-05	CbGpPWpGaD
Bexarotene—Diarrhoea—Epirubicin—hematologic cancer	3.61e-06	3.23e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—CREBBP—hematologic cancer	3.6e-06	7.84e-05	CbGpPWpGaD
Bexarotene—Hypersensitivity—Doxorubicin—hematologic cancer	3.6e-06	3.22e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—MTHFR—hematologic cancer	3.6e-06	7.83e-05	CbGpPWpGaD
Bexarotene—Vomiting—Methotrexate—hematologic cancer	3.59e-06	3.21e-05	CcSEcCtD
Bexarotene—Rash—Methotrexate—hematologic cancer	3.56e-06	3.18e-05	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—hematologic cancer	3.56e-06	3.18e-05	CcSEcCtD
Bexarotene—Headache—Methotrexate—hematologic cancer	3.54e-06	3.16e-05	CcSEcCtD
Bexarotene—Asthenia—Doxorubicin—hematologic cancer	3.51e-06	3.14e-05	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—hematologic cancer	3.49e-06	3.12e-05	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—hematologic cancer	3.46e-06	3.09e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	3.41e-06	7.42e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ARNTL—hematologic cancer	3.4e-06	7.4e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CDA—hematologic cancer	3.39e-06	7.37e-05	CbGpPWpGaD
Bexarotene—Vomiting—Epirubicin—hematologic cancer	3.36e-06	3e-05	CcSEcCtD
Bexarotene—Nausea—Methotrexate—hematologic cancer	3.35e-06	3e-05	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—hematologic cancer	3.34e-06	2.99e-05	CcSEcCtD
Bexarotene—Rash—Epirubicin—hematologic cancer	3.33e-06	2.98e-05	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—hematologic cancer	3.33e-06	2.97e-05	CcSEcCtD
Bexarotene—Headache—Epirubicin—hematologic cancer	3.31e-06	2.96e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—CA9—hematologic cancer	3.31e-06	7.2e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ACP5—hematologic cancer	3.31e-06	7.2e-05	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—hematologic cancer	3.28e-06	7.14e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NCOR2—hematologic cancer	3.27e-06	7.11e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PC—hematologic cancer	3.26e-06	7.09e-05	CbGpPWpGaD
Bexarotene—Dizziness—Doxorubicin—hematologic cancer	3.23e-06	2.89e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.17e-06	6.9e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GBA—hematologic cancer	3.15e-06	6.85e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC35B2—hematologic cancer	3.15e-06	6.85e-05	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6—hematologic cancer	3.14e-06	6.84e-05	CbGpPWpGaD
Bexarotene—Nausea—Epirubicin—hematologic cancer	3.14e-06	2.81e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—IDH1—hematologic cancer	3.11e-06	6.77e-05	CbGpPWpGaD
Bexarotene—Vomiting—Doxorubicin—hematologic cancer	3.11e-06	2.78e-05	CcSEcCtD
Bexarotene—Rash—Doxorubicin—hematologic cancer	3.08e-06	2.76e-05	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—hematologic cancer	3.08e-06	2.75e-05	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—GSTO1—hematologic cancer	3.08e-06	6.69e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TXN—hematologic cancer	3.08e-06	6.69e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCC3—hematologic cancer	3.08e-06	6.69e-05	CbGpPWpGaD
Bexarotene—Headache—Doxorubicin—hematologic cancer	3.06e-06	2.74e-05	CcSEcCtD
Bexarotene—RXRG—Gene Expression—AKT1—hematologic cancer	3.03e-06	6.59e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CG—hematologic cancer	3.02e-06	6.58e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SPHK1—hematologic cancer	3.01e-06	6.55e-05	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—hematologic cancer	2.9e-06	2.6e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—AKT1—hematologic cancer	2.9e-06	6.31e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—UGT1A1—hematologic cancer	2.89e-06	6.29e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTAP—hematologic cancer	2.88e-06	6.27e-05	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—hematologic cancer	2.85e-06	6.19e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CRABP1—hematologic cancer	2.81e-06	6.12e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC22A1—hematologic cancer	2.81e-06	6.12e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CREBBP—hematologic cancer	2.8e-06	6.1e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALOX5—hematologic cancer	2.74e-06	5.97e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CD—hematologic cancer	2.66e-06	5.78e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NUP98—hematologic cancer	2.66e-06	5.78e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALB—hematologic cancer	2.62e-06	5.71e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ADCY7—hematologic cancer	2.58e-06	5.61e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NCOA3—hematologic cancer	2.58e-06	5.61e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—FHL2—hematologic cancer	2.57e-06	5.58e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NUP214—hematologic cancer	2.56e-06	5.57e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.53e-06	5.51e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AGRN—hematologic cancer	2.52e-06	5.48e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3R1—hematologic cancer	2.51e-06	5.46e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTR—hematologic cancer	2.51e-06	5.46e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCG2—hematologic cancer	2.51e-06	5.46e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ENO2—hematologic cancer	2.46e-06	5.35e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—IDH2—hematologic cancer	2.39e-06	5.19e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HMMR—hematologic cancer	2.39e-06	5.19e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTT1—hematologic cancer	2.39e-06	5.19e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.35e-06	5.11e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SDC1—hematologic cancer	2.33e-06	5.07e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CB—hematologic cancer	2.32e-06	5.04e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ARNTL—hematologic cancer	2.24e-06	4.88e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.23e-06	4.85e-05	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MAPK3—hematologic cancer	2.2e-06	4.78e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.2e-06	4.78e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ACP5—hematologic cancer	2.18e-06	4.75e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA9—hematologic cancer	2.18e-06	4.75e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.15e-06	4.69e-05	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—hematologic cancer	2.14e-06	4.65e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.1e-06	4.58e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—IDH1—hematologic cancer	2.05e-06	4.46e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.03e-06	4.41e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.03e-06	4.41e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TXN—hematologic cancer	2.03e-06	4.41e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—hematologic cancer	2e-06	4.35e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.99e-06	4.32e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CD44—hematologic cancer	1.98e-06	4.31e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NQO1—hematologic cancer	1.98e-06	4.31e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.94e-06	4.22e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—EP300—hematologic cancer	1.91e-06	4.15e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.91e-06	4.15e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYCS—hematologic cancer	1.88e-06	4.08e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.86e-06	4.06e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.86e-06	4.04e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.86e-06	4.04e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.81e-06	3.93e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NUP98—hematologic cancer	1.75e-06	3.81e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.7e-06	3.7e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.7e-06	3.7e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NUP214—hematologic cancer	1.69e-06	3.67e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.68e-06	3.65e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.65e-06	3.6e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTR—hematologic cancer	1.65e-06	3.6e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.65e-06	3.6e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ENO2—hematologic cancer	1.62e-06	3.53e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.6e-06	3.48e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.57e-06	3.42e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.57e-06	3.41e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SDC1—hematologic cancer	1.54e-06	3.35e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.52e-06	3.31e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.52e-06	3.31e-05	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—hematologic cancer	1.48e-06	3.23e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—hematologic cancer	1.41e-06	3.07e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.34e-06	2.92e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NQO1—hematologic cancer	1.31e-06	2.84e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CD44—hematologic cancer	1.31e-06	2.84e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYCS—hematologic cancer	1.24e-06	2.69e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.23e-06	2.67e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.18e-06	2.57e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—hematologic cancer	1.15e-06	2.51e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.13e-06	2.45e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.09e-06	2.37e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.05e-06	2.28e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.03e-06	2.25e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTM1—hematologic cancer	1e-06	2.18e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NCOR1—hematologic cancer	1e-06	2.18e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CD—hematologic cancer	9.92e-07	2.16e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALB—hematologic cancer	9.79e-07	2.13e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3R1—hematologic cancer	9.36e-07	2.04e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.86e-07	1.93e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CB—hematologic cancer	8.64e-07	1.88e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—hematologic cancer	7.47e-07	1.63e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CG—hematologic cancer	7.44e-07	1.62e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—EP300—hematologic cancer	7.12e-07	1.55e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.9e-07	1.5e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CD—hematologic cancer	6.54e-07	1.42e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALB—hematologic cancer	6.46e-07	1.4e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3R1—hematologic cancer	6.18e-07	1.34e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.7e-07	1.24e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—hematologic cancer	5.27e-07	1.15e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—hematologic cancer	4.93e-07	1.07e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—EP300—hematologic cancer	4.7e-07	1.02e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—hematologic cancer	4.3e-07	9.37e-06	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.48e-07	7.56e-06	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—hematologic cancer	2.84e-07	6.18e-06	CbGpPWpGaD
